Aurélien Marabelle

59PUBLICATIONS

400CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (59)

Sort by Publication Date:

|Jul 15, 2026

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

|Jun 23, 2026

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

|Apr 29, 2026

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

|Apr 01, 2026

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Capucine Baldini, Philippe A Cassier, Jean-Pierre Delord

|Feb 25, 2026

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.

Carlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos

|Jan 13, 2026

Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer.

Sandy Chevrier, Corentin Richard, Olivier Adotévi

Pageof 10

Frequent Collaborators

9 joint publications

François-Xavier Danlos

Laurence Zitvogel

Stéphane Champiat

Nathalie Chaput

Benjamin Besse

Agathe Dubuisson

Lambros Tselikas

Jean-Eudes Fahrner

Thibault Raoult

Ignacio Melero

Frequent Collaborators

9 joint publications

François-Xavier Danlos

9 joint publications

Laurence Zitvogel

7 joint publications

Stéphane Champiat

6 joint publications

Nathalie Chaput